RxDoctor Payments Data

Frederick Kahn, MD

Psychosomatic Medicine · Paramus, NJNPI 1316160039

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Orexo US, Inc. at 53.4% of the total. Reporting peaked in 2019 at $1,602 and has fallen 67.6% since, to $519 in 2025.

$2,422in general payments, 2019–2025

Across 43 payments — averaging $56.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$1K
  • Braeburn Inc.$473
  • Kerecis Limited$218
  • Otsuka America Pharmaceutical, Inc.$166
  • Johnson & Johnson$109
  • Vanda Pharmaceuticals Inc.$35
  • plus $126 from 8 others

What the payments were for

  • Consulting fees$1,25052%
  • Travel & lodging$191%
  • Food & beverage$1,15348%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychosomatic medicine providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$181,903
Medicare patients
75
Services billed
1,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$12,300
VyvanseLisdexamfetamine Dimesylate11$4,084
Lurasidone Hcl12$3,487
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine112$3,451
Buprenorphine Hcl115$3,368
Fentanyl20$2,001
Methylphenidate Hcl30$1,724
Alprazolam223$1,392
Bupropion XlBupropion Hcl34$1,340
Clonazepam110$1,136
Olanzapine13$1,040
Divalproex Sodium32$921
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$553
Oxycodone Hcl35$499
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$14$4,08411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other psychosomatic medicine in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →